Coiled Therapeutics plc (COTXF)

Market Cap	37.13M
Revenue	n/a
Net Income	n/a
EPS	n/a
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0908
Previous Close	0.0908
Day's Range	0.0908 - 0.0908
52-Week Range	0.0908 - 0.1700
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	May 6, 2027

About Coiled Therapeutics

Coiled Therapeutics plc, a clinical-stage oncology company, develops and commercialises clinical-stage oncology therapeutics in the United Kingdom and internationally. The company’s lead asset is AO-252, a first-in-class, small molecule inhibitor of TACC3, currently in a Phase I clinical trial for advanced solid tumours, including ovarian and prostate cancer. The company also offers a STAT-6 siRNA programme targeting immunology indications such as asthma, fibrosis, eczema, and allergic disease, with plans for assessment towards Phase I clinical...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Sridhar Vempati
• Employees: 7
• Stock Exchange: OTCMKTS
• Ticker Symbol: COTXF

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 13, 2026

Data Sources Report a data error